Payment overview · 2025
General Payments
$9,195.77
23 reported records · 9 companies
Healthcare provider profile · identity verified
Jennifer Condon
Physician Assistants & Advanced Practice Nursing Providers|Nurse Practitioner · FORT DODGE, IA · NPI 1386084747
Verified facts
What the public records show
CMS Open Payments records show Jennifer Condon received $9,195.77 in general payments during 2025 across 23 reported records.
GENZYME CORPORATION accounted for 52.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 7 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Tezspire.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Symbicort by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TEZSPIRE as an associated drug or biological on 33983 records involving 10291 distinct recipient NPIs. Public Medicare Part D data also shows 31 claims for Tezspire by this doctor in 2024.
Boehringer Ingelheim Pharmaceuticals, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported OFEV as an associated drug or biological on 14236 records involving 6873 distinct recipient NPIs. Public Medicare Part D data also shows 14 claims for Ofev by this doctor in 2024.
HARMONY BIOSCIENCES LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported WAKIX as an associated drug or biological on 20652 records involving 6156 distinct recipient NPIs. Public Medicare Part D data also shows 19 claims for Wakix by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $4,781.12 | 52.0% | 8 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $4,201.92 | 45.7% | 8 | 2025 |
| HARMONY BIOSCIENCES LLC | Unresolved — no canonical attribution shown | $99.99 | 1.1% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $27.90 | 0.3% | 1 | 2025 |
| Philips North America LLC | Unresolved — no canonical attribution shown | $18.97 | 0.2% | 1 | 2025 |
| JAZZ PHARMACEUTICALS INC. | Unresolved — no canonical attribution shown | $18.93 | 0.2% | 1 | 2025 |
| Insmed, Inc. | Unresolved — no canonical attribution shown | $17.38 | 0.2% | 1 | 2025 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $15.04 | 0.2% | 1 | 2025 |
| Regeneron Healthcare Solutions, Inc. | Unresolved — no canonical attribution shown | $14.52 | 0.2% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $5,392.00 | 8 |
| Consulting Fee | $2,311.13 | 1 |
| Travel and Lodging | $1,055.96 | 4 |
| Food and Beverage | $319.31 | 8 |
| Education | $117.37 | 2 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| TEZSPIRE Normalized: tezspire |
Biological | AstraZeneca Pharmaceuticals LP | $4,201.92 | 8 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION, Regeneron Healthcare Solutions, Inc. | $1,455.30 | 4 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $27.90 | 1 | 2025 |
Source payment records
|
|||||
| Vest Therapy Und Normalized: vest therapy und |
Device | Philips North America LLC | $18.97 | 1 | 2025 |
Source payment records
|
|||||
| XYWAV Normalized: xywav |
Drug | JAZZ PHARMACEUTICALS INC. | $18.93 | 1 | 2025 |
Source payment records
|
|||||
| Brinsupri Normalized: brinsupri |
Drug | Insmed, Inc. | $17.38 | 1 | 2025 |
Source payment records
|
|||||
| JASCAYD Normalized: jascayd |
Drug | Boehringer Ingelheim Pharmaceuticals, Inc. | $15.04 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| TEZSPIRE tezspire |
2025 | Tezspire | 2024 | 31 Beneficiary count suppressed |
exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
89 | 25 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | TEZSPIRE open payments reported associated product |
CMS Open Payments — General Payments 33983 supporting records · 10291 recipient NPIs · example record 1206131392 |
Tezspire · 2024 Exact normalized brand match · 1 Part D row |
31 | suppressed by CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. Exact reporting entity; no affiliate inference |
2025 | OFEV open payments reported associated product |
CMS Open Payments — General Payments 14236 supporting records · 6873 recipient NPIs · example record 1221811762 |
Ofev · 2024 Exact normalized brand match · 1 Part D row |
14 | suppressed by CMS |
| HARMONY BIOSCIENCES LLC Exact reporting entity; no affiliate inference |
2025 | WAKIX open payments reported associated product |
CMS Open Payments — General Payments 20652 supporting records · 6156 recipient NPIs · example record 1222387076 |
Wakix · 2024 Exact normalized brand match · 1 Part D row |
19 | suppressed by CMS |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 906 | 168 |
| Prednisone | Prednisone | 574 | 269 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 537 | 195 |
| Omeprazole | Omeprazole | 292 | 88 |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 272 | 57 |
| Ventolin Hfa | Albuterol Sulfate | 264 | 81 |
| Breo Ellipta | Fluticasone/Vilanterol | 235 | 37 |
| Montelukast Sodium | Montelukast Sodium | 180 | 53 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 159 | 33 |
| Dupixent Pen | Dupilumab | 132 | 23 |
| Azithromycin | Azithromycin | 109 | 46 |
| Ropinirole Hcl | Ropinirole Hcl | 104 | 31 |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 103 | 18 |
| Symbicort | Budesonide/Formoterol Fumarate | 89 | 25 |
| Stiolto Respimat | Tiotropium Br/Olodaterol Hcl | 76 | 16 |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 73 | 19 |
| Fluticasone Propionate | Fluticasone Propionate | 71 | 16 |
| Morphine Sulfate | Morphine Sulfate | 64 | 21 |
| Mirtazapine | Mirtazapine | 61 | 21 |
| Spiriva Respimat | Tiotropium Bromide | 56 | suppressed |
| Theophylline Er | Theophylline Anhydrous | 53 | 11 |
| Dulera | Mometasone/Formoterol | 52 | 15 |
| Furosemide | Furosemide | 50 | 21 |
| Pantoprazole Sodium | Pantoprazole Sodium | 49 | 19 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 47 | 11 |
| Varenicline Tartrate | Varenicline Tartrate | 46 | 12 |
| Fasenra Pen | Benralizumab | 45 | suppressed |
| Sertraline Hcl | Sertraline Hcl | 42 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 42 | 30 |
| Advair Hfa | Fluticasone Propion/Salmeterol | 41 | suppressed |
| Eliquis | Apixaban | 41 | suppressed |
| Levalbuterol Tartrate Hfa | Levalbuterol Tartrate | 39 | suppressed |
| Dupixent Syringe | Dupilumab | 38 | suppressed |
| Nucala | Mepolizumab | 38 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 35 | suppressed |
| Modafinil | Modafinil | 34 | suppressed |
| Armodafinil | Armodafinil | 32 | suppressed |
| Arnuity Ellipta | Fluticasone Furoate | 31 | suppressed |
| Tezspire | Tezepelumab-Ekko | 31 | suppressed |
| Nystatin | Nystatin | 29 | 20 |
| Sunosi | Solriamfetol Hcl | 27 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 26 | suppressed |
| Potassium Chloride | Potassium Chloride | 26 | suppressed |
| Roflumilast | Roflumilast | 26 | suppressed |
| Advair Diskus | Fluticasone Propion/Salmeterol | 24 | suppressed |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 24 | 19 |
| Ipratropium Bromide | Ipratropium Bromide | 24 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 23 | suppressed |
| Methylphenidate Hcl | Methylphenidate Hcl | 22 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 21 | suppressed |
| Trazodone Hcl | Trazodone Hcl | 21 | suppressed |
| Metoprolol Tartrate | Metoprolol Tartrate | 20 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 19 | suppressed |
| Metoprolol Succinate | Metoprolol Succinate | 19 | suppressed |
| Wakix | Pitolisant Hcl | 19 | suppressed |
| Fluconazole | Fluconazole | 18 | 17 |
| Opsumit | Macitentan | 18 | suppressed |
| Wixela Inhub | Fluticasone Propion/Salmeterol | 18 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 15 | suppressed |
| Methotrexate | Methotrexate Sodium | 14 | suppressed |
| Ofev | Nintedanib Esylate | 14 | suppressed |
| Bumetanide | Bumetanide | 13 | suppressed |
| Fluticasone Propionate Hfa | Fluticasone Propionate | 13 | suppressed |
| Neupro | Rotigotine | 13 | suppressed |
| Alprazolam | Alprazolam | 12 | suppressed |
| Aralast Np | Alpha-1-Proteinase Inhibitor | 12 | suppressed |
| Asmanex Hfa | Mometasone Furoate | 12 | suppressed |
| Lorazepam | Lorazepam | 12 | suppressed |
| Ambrisentan | Ambrisentan | 11 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 11 | suppressed |
| Tadalafil | Tadalafil | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $9,195.77 · 23 records | GENZYME CORPORATION | Brinsupri, DUPIXENT, INSPIRE, JASCAYD, TEZSPIRE, Vest Therapy Und, XYWAV | 4 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Tezspire play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with AstraZeneca Pharmaceuticals LP?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error